Escherichia coli promotes DSS‑induced murine colitis recovery through activation of the TLR4/NF‑κB signaling pathway

Lu,Jiabao; Dong,Boye; Chen,Ailan; He,Feng; Peng,Baifu; Wu,Zixin; Cao,Jie; Li,Wanglin

doi:10.3892/mmr.2019.9848

Escherichia coli promotes DSS‑induced murine colitis recovery through activation of the TLR4/NF‑κB signaling pathway

Authors:
- Jiabao Lu
- Boye Dong
- Ailan Chen
- Feng He
- Baifu Peng
- Zixin Wu
- Jie Cao
- Wanglin Li
View Affiliations

Affiliations: Department of Colorectal Surgery, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510180, P.R. China, Department of Cardiology, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510120, P.R. China, Department of Colorectal Surgery, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, Guangdong 510180, P.R. China
Published online on: January 11, 2019 https://doi.org/10.3892/mmr.2019.9848
Pages: 2021-2028
Copyright: © Lu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Increasing evidence suggests that intestinal microbiota have critical function in the pathogenesis of inflammatory bowel disease. This present study investigated the effects of Escherichia coli (E. coli) in mice with dextran sulfate sodium (DSS)‑induced colitis. Furthermore, Toll‑like receptor 4 (TLR4) and nuclear factor‑κB (NF‑κB) gene expression was measured by reverse transcription‑quantitative polymerase chain reaction. In total, two experiments were performed. In the first experiment, four groups were established in BALB/c mice: i) Group A, control (no treatments); ii) group B, DSS‑induced colitis; iii) group C, DSS‑induced colitis bacteria depleted (BD) mice; and iv) group D, E. coli‑treated DSS‑induced colitis BD mice. In the second experiment, there were three groups: i) Group A1, control C57BL/6 mice; ii) group B1, E. coli‑treated DSS‑induced colitis BD C57BL/6 mice; and iii) E. coli‑treated DSS‑induced colitis BD TLR4‑/‑ mice. Clinical outcomes, colon and immune histopathology and tissue myeloperoxidase activity were assessed. Mice with DSS‑induced colitis that were treated with E. coli exhibited enhanced recovery, with significantly improved clinical and histological scores compared with the DSS only group. The mRNA expression of TLR4 and NF‑κB in the E. coli‑treated group was also significantly higher. These effects were abolished in TLR4‑/‑ mice, suggesting that E. coli may have promoted recovery through the TLR4 pathway. The present study indicated that E. coli promoted recovery from DSS‑induced colitis in mice, potentially through activation of the TLR4/NF‑κB signaling pathway.

View Figures

View References

1	Baumgart DC and Sandborn WJ: Inflammatory bowel disease: Clinical aspects and established and evolving therapies. Lancet. 369:1641–1657. 2007. View Article : Google Scholar : PubMed/NCBI
2	Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE and Büchler MW: Characterisation of acute murine dextran sodium sulphate colitis: Cytokine profile and dose dependency. Digestion. 62:240–248. 2000. View Article : Google Scholar : PubMed/NCBI
3	Prideaux L, Kamm MA, De Cruz PP, Chan FK and Ng SC: Inflammatory bowel disease in Asia: A systematic review. J Gastroenterol Hepatol. 27:1266–1280. 2012. View Article : Google Scholar : PubMed/NCBI
4	Sellon RK, Tonkonogy S, Schultz M, Dieleman LA, Grenther W, Balish E, Rennick DM and Sartor RB: Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 66:5224–5231. 1998.PubMed/NCBI
5	Blum AM, Metwali A, Elliott DE, Berg DJ and Weinstock JV: CD4+ T cells from IL-10-deficient mice transfer susceptibility to NSAID-induced Rag colitis. Am J Physiol Gastrointest Liver Physiol. 287:G320–G325. 2004. View Article : Google Scholar : PubMed/NCBI
6	Rutgeerts P, Goboes K, Peeters M, Hiele M, Penninckx F, Aerts R, Kerremans R and Vantrappen G: Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet. 338:771–774. 1991. View Article : Google Scholar : PubMed/NCBI
7	Khan KJ, Ullman TA, Ford AC, Abreu MT, Abadir A, Marshall JK, Talley NJ and Moayyedi P: Antibiotic therapy in inflammatory bowel disease: A systematic review and meta-analysis. Am J Gastroenterol. 106:661–673. 2011. View Article : Google Scholar : PubMed/NCBI
8	Ananthakrishnan AN, Hur C, Juillerat P and Korzenik JR: Strategies for the prevention of postoperative recurrence in Crohn's disease: Results of a decision analysis. Am J Gastroenterol. 106:2009–2017. 2011. View Article : Google Scholar : PubMed/NCBI
9	Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, Lee JC, Schumm LP, Sharma Y, Anderson CA, et al: Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 491:119–124. 2012. View Article : Google Scholar : PubMed/NCBI
10	Chen J, Xie L, Toyama S, Hünig T, Takahara S, Li XK and Zhong L: The effects of Foxp3-expressing regulatory T cells expanded with CD28 superagonist antibody in DSS-induced mice colitis. Int Immunopharmacol. 11:610–617. 2011. View Article : Google Scholar : PubMed/NCBI
11	National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals: Guide for the Care and Use of Laboratory Animals. 8th. National Academies Press (US); Washington, DC: 2011
12	Cooper HS, Murthy SN, Shah RS and Sedergran DJ: Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 69:238–249. 1993.PubMed/NCBI
13	Loher F, Schmall K, Freytag P, Landauer N, Hallwachs R, Bauer C, Siegmund B, Rieder F, Lehr HA, Dauer M, et al: The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. J Pharmacol Exp Ther. 305:549–556. 2003. View Article : Google Scholar : PubMed/NCBI
14	Moriyama I, Ishihara S, Rumi MA, Aziz MD, Mishima Y, Oshima N, Kadota C, Kadowaki Y, Amano Y and Kinoshita Y: Decoy oligodeoxynucleotide targeting activator protein-1 (AP-1) attenuates intestinal inflammation in murine experimental colitis. Lab Invest. 88:652–663. 2008. View Article : Google Scholar : PubMed/NCBI
15	Krawisz JE, Sharon P and Stenson WF: Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology. 87:1344–1350. 1984.PubMed/NCBI
16	Becker C, Neurath MF and Wirtz S: The intestinal microbiota in inflammatory bowel disease. ILAR J. 56:192–204. 2015. View Article : Google Scholar : PubMed/NCBI
17	Bantel H, Berg C, Vieth M, Stolte M, Kruis W and Schulze-Osthoff K: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 95:3452–3457. 2000. View Article : Google Scholar : PubMed/NCBI
18	Zhang T, Su J, Guo B, Wang K, Li X and Liang G: Apigenin protects blood-brain barrier and ameliorates early brain injury by inhibiting TLR4-mediated inflammatory pathway in subarachnoid hemorrhage rats. Int Immunopharmacol. 28:79–87. 2015. View Article : Google Scholar : PubMed/NCBI
19	Wang CX, Xie GB, Zhou CH, Zhang XS, Li T, Xu JG, Li N, Ding K, Hang CH, Shi JX and Zhou ML: Baincalein alleviates early brain injury after experimental subarachnoid hemorrhage in rats: Possible involvement of TLR4/NF-κB-mediated inflammatory pathway. Brain Res 1594. 245–255. 2015. View Article : Google Scholar
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Ray A and Dittel BN: Interrelatedness between dysbiosis in the gut microbiota due to immunodeficiency and disease penetrance of colitis. Immunology. 146:359–368. 2015. View Article : Google Scholar : PubMed/NCBI
22	Loh G and Blaut M: Role of commensal gut bacteria in inflammatory bowel diseases. Gut Microbes. 3:544–555. 2012. View Article : Google Scholar : PubMed/NCBI
23	Vigsnaes LK, van den Abbeele P, Sulek K, Frandsen HL, Steenholdt C, Brynskov J, Vermeiren J, van de Wiele T and Licht TR: Microbiotas from UC patients display altered metabolism and reduced ability of LAB to colonize mucus. Sci Rep. 3:11102013. View Article : Google Scholar : PubMed/NCBI
24	Schultz M, Veltkamp C, Dieleman LA, Grenther WB, Wyrick PB, Tonkonogy SL and Sartor RB: Lactobacillus plantarum 299V in the treatment and prevention of spontaneous colitis in interleukin-10-deficient mice. Inflamm Bowel Dis. 8:71–80. 2002. View Article : Google Scholar : PubMed/NCBI
25	Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermúdez-Humarán LG, Smirnova N, Bergé M, Sulpice T, Lahtinen S, et al: Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: Molecular mechanisms and probiotic treatment. EMBO Mol Med. 3:559–572. 2011. View Article : Google Scholar : PubMed/NCBI
26	Zhang R, Ito S, Nishio N, Cheng Z, Suzuki H and Isobe KI: Dextran sulphate sodium increases splenic Gr1(+)CD11b(+) cells which accelerate recovery from colitis following intravenous transplantation. Clin Exp Immunol. 164:417–427. 2011. View Article : Google Scholar : PubMed/NCBI
27	Fabrega MJ, Rodriguez-Nogales A, Garrido-Mesa J, Algieri F, Badía J, Giménez R, Gálvez J and Baldomà L: Intestinal Anti-inflammatory effects of outer membrane vesicles from Escherichia coli nissle 1917 in DSS-experimental colitis in mice. Front Microbiol. 8:12742017. View Article : Google Scholar : PubMed/NCBI
28	French N and Pettersson S: Microbe-host interactions in the alimentary tract: The gateway to understanding inflammatory bowel disease. Gut. 47:162–163. 2000. View Article : Google Scholar : PubMed/NCBI